The Library

Allosteric inhibition of cobalt binding to albumin by fatty acids : implications for the detection of myocardial ischemia

Tools

Luisier, J., Stewart, Alan J., Sadler, P. J., Pinheiro, Teresa J. T. and Blindauer, Claudia A.. (2012) Allosteric inhibition of cobalt binding to albumin by fatty acids : implications for the detection of myocardial ischemia. Journal of Medicinal Chemistry, Vol.55 (No.9). pp. 4425-4430. ISSN 0022-2623

[img]
Preview
 Text
WRAP_Pinheiro_495_JLu_Manuscript_JMedChem_revisions_02042012.pdf - Accepted Version
Download (820Kb) | Preview

Abstract

The biomarker "ischemia-modified albumin" (IMA), measured by the albumin-cobalt-binding assay (ACB assay), is the only FDA-approved biomarker for early diagnosis of myocardial ischemia. On the basis of the hypothesis that high levels of free fatty acids are directly responsible for reduction in cobalt binding by albumin, chemically defined model systems consisting of bovine serum albumin, Co(2+), and myristate were studied by isothermal titration calorimetry, (111)Cd NMR spectroscopy, and ACB assays. Significantly reduced Co(2+) binding to albumin, as demonstrated by an increase in the absorption of the Co-dithiothreitol adduct, elicited by adding ca. 3 mol equiv of myristate, was comparable to that observed in clinical ACB assays. Levels of free fatty acids are elevated during myocardial ischemia but also in other conditions that have been correlated with high IMA values. Hence, IMA may correspond to albumin with increased levels of bound fatty acids, and all clinical observations can be rationalized by this molecular mechanism.

Item Type: Journal Article
Subjects: Q Science > QD Chemistry
Q Science > QP Physiology
Divisions: Faculty of Science > Chemistry
Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH): Allosteric regulation, Fatty acids, Reduction (Chemistry), Coronary heart disease -- Diagnosis, Cobalt, Albumins, Cooperative binding (Biochemistry)
Journal or Publication Title: Journal of Medicinal Chemistry
Publisher: American Chemical Society
ISSN: 0022-2623
Official Date: 10 May 2012
Volume: Vol.55
Number: No.9
Page Range: pp. 4425-4430
Identification Number: 10.1021/jm3003137
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Biotechnology and Biological Sciences Research Council (Great Britain) (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), BP (Firm), Royal Society (Great Britain), European Research Council (ERC)
Grant number: BB/D524516/1 (BBSRC)
References:

1. Gaze, D. C., Ischemia Modified Albumin: A Novel Biomarker for the Detection of Cardiac Ischemia. Drug Metab. Pharmacokinet. 2009, 24, 333-341.
2. Collinson, P. O.; Gaze, D. C., Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J. Clin. Pathol. 2008, 61, 1025-1028.
3. Sbarouni, E.; Georgiadou, P.; Voudris, V., Ischemia modified albumin changes - review and clinical implications. Clin. Chem. Lab. Med. 2011, 49, 177-184.
4. Apple, F. S.; Wu, A. H. B.; Mair, J.; Ravkilde, J.; Panteghini, M.; Tate, J.; Pagani, F.; Christenson, R. H.; Mockel, M.; Danne, O.; Jaffe, A. S., Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 2005, 51, 810-824.
5. Bar-Or, D.; Lau, E.; Winkler, J. V., A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 2000, 19, 311-315.
6. Bhagavan, N. V.; Lai, E. M.; Rios, P. A.; Yang, J. S.; Ortega-Lopez, A. M.; Shinoda, H.; Honda, S. A. A.; Rios, C. N.; Sugiyama, C. E.; Ha, C. E., Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin. Chem. 2003, 49, 581-585.
7. Christenson, R. H.; Duh, S. H.; Sanhai, W. R.; Wu, A. H. B.; Holtman, V.; Painter, P.; Branham, E.; Apple, F. S.; Murakami, M.; Morris, D. L., Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: A multicentre study. Clin. Chem. 2001, 47, 464-470.
8. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P., Current role of ischemia-modified albumin in routine clinical practice. Biomarkers 2010, 15, 655-662.
9. Amirtharaj, G. J.; Natarajan, S. K.; Mukhopadhya, A.; Zachariah, U. G.; Hegde, S. K.; Kurian, G.; Balasubramanian, K. A.; Ramachandran, A., Fatty acids influence binding of cobalt to serum albumin in patients with fatty liver. Biochim. Biophys. Acta-Mol. Basis Dis. 2008, 1782, 349-354.
10. Kaefer, M.; Piva, S. J.; De Carvalho, J. A. M.; Da Silva, D. B.; Becker, A. M.; Coelho, A. C.; Duarte, M.; Moresco, R. N., Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin. Biochem. 2010, 43, 450-454.
11. Kim, J. S.; Hwang, H. J.; Ko, Y. G.; Kim, J. S.; Choi, D.; Ha, J. W.; Hong, M. K.; Jang, Y., Ischemia-Modified Albumin: Is It a Reliable Diagnostic and Prognostic Marker for Myocardial Ischemia in Real Clinical Practice? Cardiology 2010, 116, 123-129.
12. Hjortshoj, S.; Kristensen, S. R.; Ravkilde, J., Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am. J. Emerg. Med. 2010, 28, 170-176.
13. Bar-Or, D.; Curtis, G.; Rao, N.; Bampos, N.; Lau, E., Characterization of the Co2+ and Ni2+ binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur. J. Biochem. 2001, 268, 42-47.
14. Bar-Or, D.; Rael, L. T.; Bar-Or, R.; Slone, D. S.; Mains, C. W.; Rao, N. K.; Curtis, C. G., The cobalt-albumin binding assay: insights into its mode of action. Clin. Chim. Acta 2008, 387, 120-127.
15. Lopaschuk, G. D.; Ussher, J. R.; Folmes, C. D. L.; Jaswal, J. S.; Stanley, W. C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90, 207-258.
16. Bhagavan, N. V.; Ha, J. S.; Park, J. H.; Honda, S. A.; Rios, C. N.; Sugiyama, C.; Fujitani, G. K.; Takeuchi, I. K.; Ha, C. E., Utility of serum fatty acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia-modified albumin: A pilot study. Clin. Chem. 2009, 55, 1588-1590.
17. van der Vusse, G. J., Albumin as fatty acid transporter. Drug Metab. Pharmacokinet. 2009, 24, 300-307.
18. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N., Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nature Struct. Biol. 1998, 5, 827-835.
19. Lu, J.; Stewart, A. J.; Sleep, D.; Sadler, P. J.; Pinheiro, T. J. T.; Blindauer, C. A., A molecular mechanism for modulating plasma Zn speciation by fatty acids. J. Am. Chem. Soc. 2012, 134, 1454-1457.
20. Mothes, E.; Faller, P., Evidence that the principal Co(II)-binding site in human serum albumin is not at the N-terminus: Implication on the albumin cobalt binding test for detecting myocardial ischemia. Biochemistry 2007, 46, 2267-2274.
21. Peters, T., Jr., All about albumin:Biochemistry, genetics, and medical applications. Academic Press: San Diego, London, 1996.
22. Masuoka, J.; Saltman, P., Zinc(II) and copper(II) binding to serum-albumin - a comparative-study of dog, bovine, and human albumin. J. Biol. Chem. 1994, 269, 25557-25561.
23. Bal, W.; Christodoulou, J.; Sadler, P. J.; Tucker, A., Multi-metal binding site of serum albumin. J. Inorg. Biochem. 1998, 70, 33-39.
24. Lu, J.; Stewart, A. J.; Sadler, P. J.; Pinheiro, T. J. T.; Blindauer, C. A., Albumin as a zinc carrier: Properties of its high-affinity zinc-binding site. Biochem. Soc. Trans. 2008, 36, 1317-1321.
25. Harford, C.; Sarkar, B., Amino terminal Cu(II)- and Ni(II)-binding (ATCUN) motif of proteins and peptides: Metal binding, DNA cleavage, and other properties. Acc. Chem. Res. 1997, 30, 123-130.
26. Blindauer, C. A.; Harvey, I.; Bunyan, K. E.; Stewart, A. J.; Sleep, D.; Harrison, D. J.; Berezenko, S.; Sadler, P. J., Structure, properties, and engineering of the major zinc binding site on human albumin. J. Biol. Chem. 2009, 284, 23116-23124.
27. Martin, E. O.; Drakenberg, T., Cadmium(II), zinc(II), and copper(II) ions binding to bovine serum albumin. A 113Cd NMR study. Inorg. Chim. Acta 1982, 67, 71-74.
28. Goumakos, W.; Laussac, J. P.; Sarkar, B., Binding of cadmium(II) and zinc(II) to human and dog serum albumins - an equilibrium dialysis and Cd-113-NMR study. Biochem. Cell Biol. 1991, 69, 809-820.
29. Sadler, P. J.; Viles, J. H., 1H and 113Cd nmr investigations of Cd2+ and Zn2+ binding sites on serum albumin: Competition with Ca2+, Ni2+, Cu2+, and Zn2+. Inorg. Chem. 1996, 35, 4490-4496.
30. Sokolowska, M.; Wszelaka-Rylik, M.; Poznanski, J.; Bal, W., Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II) ions in human serum albumin. J. Inorg. Biochem. 2009, 103, 1005-1013.
31. Lakusta, H.; Sarkar, B., Equilibrium studies of zinc(II) and cobalt(II) binding to tripeptide analogs of the amino terminus of human serum albumin. J. Inorg. Biochem. 1979, 11, 303-315.
32. Sadler, P. J.; Tucker, A.; Viles, J. H., Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding-site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. Eur. J. Biochem. 1994, 220, 193-200.
33. Liang, H.; Huang, J.; Tu, C. Q.; Zhang, M.; Zhou, Y. Q.; Shen, P. W., The subsequent effect of interaction between Co2+ and human serum albumin or bovine serum albumin. J. Inorg. Biochem. 2001, 85, 167-171.
34. Krezel, A.; Lesniak, W.; Jezowska-Bojczuk, M.; Mlynarz, P.; Brasun, J.; Kozlowski, H.; Bal, W., Coordination of heavy metals by dithiothreitol, a commonly used thiol group protectant. J. Inorg. Biochem. 2001, 84, 77-88.
35. Sugio, S.; Kashima, A.; Mochizuki, S.; Noda, M.; Kobayashi, K., Crystal structure of human serum albumin at 2.5 angstrom resolution. Protein Eng. 1999, 12, 439-446.
36. Hendrickson, S. C.; StLouis, J. D.; Lowe, J. E.; Abdelaleem, S., Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol. Cell. Biochem. 1997, 166, 85-94.
37. Apple, F. S.; Kleinfeld, A.M.; Adams, III J. Unbound free fatty acid concentrations are increased in cardiac ischemia. Clin. Proteomics J. 2004, 1, 41-44.
38. da Silva, S. H.; Pereira, R. D.; Hausen, B. D.; Signor, C.; Gomes, P.; de Campos, M. M. A.; Moresco, R. N., Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome. Clin. Chem. Lab. Med. 2011, 49, 541-546.
39. Breitling, L. P.; Rothenbacher, D.; Grandi, N. C.; Marz, W.; Brenner, H., Prognostic usefulness of free fatty acids in patients with stable coronary heart disease. Am. J. Cardiol. 2011, 108, 508-513.
40. Stewart, A. J.; Blindauer, C. A.; Berezenko, S.; Sleep, D.; Sadler, P. J., Interdomain zinc site on human albumin. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3701-3706.
41. Fasman, D. G., Practical Handbook of Biochemistry and Molecular Biology, Boston, CRC Press, 1992.
URI: http://wrap.warwick.ac.uk/id/eprint/50369

Request changes to a record

Actions (login required)

View Item View Item

Document Downloads

More statistics for this item...